<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Previous evidence suggests that treatment with 3-hydroxy-3-methylglutaryl-<z:chebi fb="3" ids="15346">coenzyme-A</z:chebi> reductase inhibitors (<z:chebi fb="0" ids="35664">statins</z:chebi>) has a positive impact on <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We decided to investigate the association between the use of <z:chebi fb="0" ids="35664">statins</z:chebi> and the prevalence of <z:hpo ids='HP_0000726'>dementia</z:hpo> and <z:chebi fb="0" ids="35664">statins</z:chebi>' impact on the progression of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This is a case-control and a retrospective cohort study of a community-based ambulatory primary care geriatric practice </plain></SENT>
<SENT sid="3" pm="."><plain>We included a convenience sample of <z:hpo ids='HP_0000001'>all</z:hpo> patients (N = 655, mean age 78.7 +/- 0.3 years, 85% Caucasian, 74% women) with <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> or <z:hpo ids='HP_0000726'>dementia</z:hpo>, or using <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>We compared those using <z:chebi fb="0" ids="35664">statins</z:chebi> with those who do not with respect to the clinical diagnosis of <z:hpo ids='HP_0000726'>dementia</z:hpo> and its subtypes and the progression of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At the initial visit, 35% had <z:hpo ids='HP_0000726'>dementia</z:hpo>, and 17% were using <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>After covariate adjustments, patients on <z:chebi fb="0" ids="35664">statins</z:chebi> were less likely to have <z:hpo ids='HP_0000726'>dementia</z:hpo> (odds ratio [OR] for <z:hpo ids='HP_0000726'>dementia</z:hpo> based on composite definition = 0.23; 95% confidence interval [CI] [0.1-0.56], p =.001, OR <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> = 0.37; 95% CI [0.19-0.74], p =.005, OR vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> = 0.25; 95% CI [0.08-0.85], p =.027) </plain></SENT>
<SENT sid="7" pm="."><plain>At follow-up, patients on <z:chebi fb="0" ids="35664">statins</z:chebi> showed an improvement on their Mini-Mental Status Examination score by 0.7 +/- 0.4 compared to a decline by 0.5 +/- 0.3 in controls, p =.025 (OR for no change or improvement on <z:chebi fb="0" ids="35664">statins</z:chebi> = 2.81; 95% CI [1.02-8.43], p =.045) and scored higher on the Clock Drawing Test (difference of 1.5 +/- 0.1, p =.036) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The use of <z:chebi fb="0" ids="35664">statins</z:chebi> is associated with a lower prevalence of <z:hpo ids='HP_0000726'>dementia</z:hpo> and has a positive impact on the progression of <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
</text></document>